KFDA Issues Revised Approval Specifications on Neurontin

The Korea Food and Drug Administration has recently issued the revised market approval specifications on Pfizer Korea's Neurontin (active ingredient: gabapentin) products.

Currently, Neurontin is available in the domestic market for postherpetic neuralgia (PHN) management and epilepsy treatment, and it is marketed in the form of capsules, tablets and oral solution, all of which are subject t...